Status:
COMPLETED
A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON
Lead Sponsor:
Ferring Pharmaceuticals
Conditions:
Prostate Cancer
Eligibility:
MALE
Brief Summary
This study is a large observational study, set-up to observe how long-term treatment with FIRMAGON (hormone regulator) compare to other treatments in regards to cardiovascular events, changes in bone ...
Eligibility Criteria
Inclusion
- Diagnosed with prostate cancer and indicated for androgen deprivation therapy (ADT)
- Decision made to prescribe ADT prior to enrolment
- Willing and able to provide written informed consent
Exclusion
- Participation in an interventional clinical study in which any treatment or follow-up is mandated
- Treatment with a GnRH receptor antagonist other than FIRMAGON
- Had previous or is currently under hormonal management of prostate cancer, except for subjects who have undergone therapy with curative intention where neoadjuvant/adjuvant therapy allowed for maximum 6 months. Treatment should be terminated at least 6 months prior to baseline.
Key Trial Info
Start Date :
January 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 27 2018
Estimated Enrollment :
1493 Patients enrolled
Trial Details
Trial ID
NCT01234350
Start Date
January 1 2011
End Date
March 27 2018
Last Update
June 25 2019
Active Locations (160)
Enter a location and click search to find clinical trials sorted by distance.
1
Onze-Lieve-Vrouwziekenhuis
Aalst, Belgium
2
Ziekenhuisnetwerk Antwerpen - AZ Stuivenberg
Antwerp, Belgium
3
AZ Sint-Jan AV
Bruges, Belgium
4
Hôpitaux IRIS Sud
Brussels, Belgium